Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06466603 · ClinicalTrials.gov registry record
Probiotics for Anxiety Study
A clinical trial of Anxiety, sponsored by Verb Biotics.
- Active
- Registry status
- 122
- Enrollment target
- 1
- Study location
NCT06466603: Active study of Anxiety, sponsored by Verb Biotics.
NCT06466603 is a study of Anxiety that is active but no longer recruiting, run by Verb Biotics. The registered enrollment target is 122 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06466603, a study of Anxiety, is active but no longer recruiting, sponsored by Verb Biotics.
- ACTIVE NOT RECRUITING
- Registry status
- 122 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to observe the effect of a consumer-grade probiotic capsule called GABA (gamma-aminobutyric acid ) Probiotic ("Study Product"), a probiotic capsule containing Lactiplantibacillus plantarum 815, on anxiety. The purpose of this study is to evaluate the effects of 2 different doses of this probiotic study product on anxiety in comparison to placebo. Additionally, the study aims to observe the effects of the probiotic study product on mood, cognitive function, quality of life and sleep. After the 6-week study product use period, all participants will be given the option to continue using GABA Probiotic for an additional 4 weeks. Participants in this study will complete surveys and questionnaires about their experience before, during and after taking the study product. Additionally, this study will incorporate the use of a wrist-worn electronic device to measure sleep.
Primary Outcome
Change in Generalized Anxiety Disorder-7 (GAD-7) score by 4 points between placebo and study product groups. Baseline period will be compared as well GAD-7 scores between the 2 doses. Scores range from 0 to 21, higher scores indicating a worse outcome.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo Group
- DIETARY_SUPPLEMENT GABA Probiotic Dose 1
- DIETARY_SUPPLEMENT GABA Probiotic Dose 2
Study Locations (1)
California
- People Science, Inc. - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2024-03-04 |
| Est. Completion | 2025-02-11 |
What the registry record for NCT06466603 still lists
NCT06466603 is an observational study that tracks outcomes without assigning an intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Anxiety appearing as the primary indexed condition, and to 3 interventions - of which Placebo Group is the first listed.
NCT06466603 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06466603 about?
NCT06466603 is a clinical study titled "Probiotics for Anxiety Study". The purpose of this study is to observe the effect of a consumer-grade probiotic capsule called GABA (gamma-aminobutyric acid ) Probiotic ("Study Product"), a probiotic capsule containing Lactiplantibacillus plantarum 815, on anxiety. The purpose of this study is to evaluate the effects of 2 differe...
What is the current status of trial NCT06466603?
This trial is currently active not recruiting. The enrollment target is 122 participants. The study started on 2024-03-04. Estimated completion is 2025-02-11.
What conditions does trial NCT06466603 study?
This clinical trial studies the following conditions: Anxiety.
What interventions are being tested in trial NCT06466603?
The interventions under investigation include: Placebo Group (DIETARY_SUPPLEMENT), GABA Probiotic Dose 1 (DIETARY_SUPPLEMENT), GABA Probiotic Dose 2 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06466603?
This trial is sponsored by Verb Biotics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06466603 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06466603's enrollment target sits among peer trials
122 138th of 364 higher than 227 of 364 other Anxiety trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Digital Intervention for Physical Activity
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
-
Personalized Feedback Intervention for Latinx Drinkers With Anxiety
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI